Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Seligiline transdermal system in depression.

Paul J Goodnick1

  • 1Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Carrier Clinic, POB 147, 252 CR 601, Belle Mead, NJ 08502, USA. pgoodnick@aol.com

Expert Opinion on Pharmacotherapy
|December 14, 2006
PubMed
Summary

Selegiline transdermal system offers an effective daily treatment for major depressive disorder, with the 6 mg/24h dose showing safety and efficacy without dietary restrictions. Continued treatment demonstrated significant benefits over 52 weeks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bipolar depression: a review of randomised clinical trials.

Expert opinion on pharmacotherapy·2006
Same author

Anticonvulsants in the treatment of bipolar mania.

Expert opinion on pharmacotherapy·2006
Same author

Higher than Physician's Desk Reference (US) doses on atypical antipsychotics.

Expert opinion on drug safety·2005
Same author

The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication.

The Journal of clinical psychiatry·2004
Same author

Aripiprazole: profile on efficacy and safety.

Expert opinion on pharmacotherapy·2002
Same author

Antipsychotics: impact on prolactin levels.

Expert opinion on pharmacotherapy·2002

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Selegiline, a monoamine oxidase inhibitor, is FDA-approved for Parkinson's disease.
  • Transdermal selegiline demonstrates efficacy for major depressive disorder (MDD).

Purpose of the Study:

  • To evaluate the efficacy and safety of daily transdermal selegiline for MDD treatment.
  • To assess required dietary precautions and potential drug interactions.

Main Methods:

  • Two clinical trials assessed selegiline dosages (6, 9, 12 mg/24h).
  • A 52-week randomized prevention study evaluated treatment continuation.
  • Tyramine challenge studies and safety data analysis were conducted.

Main Results:

Related Experiment Videos

  • The 6 mg/24h dose was effective and did not require dietary precautions.
  • Higher doses showed potential for similar safety, but data is limited.
  • No hypertensive crises were reported; tyramine studies indicated a safety margin.
  • Common side effects included orthostatic hypotension and insomnia; application site reactions were frequent.
  • Contraindicated drugs include SSRIs, SNRIs, and certain analgesics due to serotonin syndrome risk.

    • Conclusions:

    • Transdermal selegiline is a viable daily treatment for MDD, particularly the 6 mg/24h dose.
    • Careful management of drug interactions is crucial, requiring medication cessation periods before and after treatment.
    • Long-term treatment appears beneficial and safe with appropriate monitoring.